A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice

Molecular Neurodegeneration

Volumn 10, Issue 1, 2015, Pages

  Neumann, Ulf ^a   Rueeger, Heinrich ^b   MacHauer, Rainer ^b   Veenstra, Siem Jacob ^b   Lueoend, Rainer M ^b   Tintelnot Blomley, Marina ^b   Laue, Grit ^b   Beltz, Karen ^b   Vogg, Barbara ^b   Schmid, Peter ^a,c   Frieauff, Wilfried ^b   Shimshek, Derya R ^a   Staufenbiel, Matthias ^a,d   Jacobson, Laura H ^a,e  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Global Discover Chemistry   (Switzerland)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; Amyloid ; BACE 1; Inhibitor; Neuroinflammation

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE INHIBITOR; NB 360; TRITON X 100; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); ASPARTIC PROTEINASE; BACE1 PROTEIN, MOUSE; HYBRID PROTEIN; NB-360; NERVE PROTEIN; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT; PICOLINIC ACID DERIVATIVE; SECRETASE; THIAZINE DERIVATIVE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTROCYTE; BRAIN CORTEX; CELL ACTIVATION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TRANSPORT; ENZYME INHIBITION; FEMALE; FOREBRAIN; HAIR DISCOLORATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; RAT; TRANSGENIC MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GENETICS; HAIR COLOR; HAMSTER; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; SECRETION (PROCESS);

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; ASTROCYTES; BRAIN; CHO CELLS; CRICETINAE; CRICETULUS; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; HAIR COLOR; HUMANS; MICE; MICE, TRANSGENIC; MICROGLIA; MUTATION; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PICOLINIC ACIDS; RATS; RECOMBINANT FUSION PROTEINS; THIAZINES;

EID: 84941317195     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/s13024-015-0033-8     Document Type: Article

References (31)

1. Masters CL, Selkoe DJ. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006262.
2. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322-33.
3. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Alzheimer's disease cooperative study steering committee; Solanezumab study group phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:311-21.
4. Wang J, Tan L, Wang HF, Tan CC, Meng XF, Wang C, et al. Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis. J Alz Dis. 2015;44:385-96.
5. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357-67.
6. Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem. 2014;130:4-28.
7. Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014;13:319-29.
8. Oehlrich D, Prokopcova H, Gijsen HJM. The evolution of amidine-based brain penetrant BACE1 inhibitors. Bioorg Med Chem Lett. 2014;24:2033-45.
9. Swahn B-M, Kolmodin K, Karlström S, von Berg S, Söderman P, Holenz J, et al. Design and Synthesis of β-Site Amyloid predursor Protein Cleaving enzyme (BACE1) inhibitors with in vivo Brain reduction of β-Amyloid Peptides. J Med Chem. 2012;55:9346-61.
10. May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, et al. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015;35:1199-210.
11. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, et al. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci. 2011;31:16507-16.
12. Fielden MR, Werner J, Jamison JA, Coppi A, Hickman D, Dunn RT, et al. Retinal toxicity induced by a novel β-secretase inhibitor in the sprague-dawley rat. Toxicol Pathol. 2015;43:581-92.
13. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeability assay in the description of passive absorption processes. J Med Chem. 1998;41:1007-10.
14. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008;36:268-75.
15. Head E. A canine model of human aging and Alzheimer's disease. Biochim Biophys Acta. 2013;1832:1384-9.
16. Lu Y, Barton HA, Leung L, Zhang L, Hajos-Korcsok E, Nolan CE, et al. Cerebrospinal fluid β-Amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses. Neurodeg Dis. 2013;12:36-50.
17. Rabe S, Reichwald J, Ammaturo D, de Strooper B, Saftig P, Neumann U, et al. The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing. J Neurochem. 2011;119:231-9.
18. McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem. 2007;282:26326-34.
19. Yamakawa H, Yagishita S, Futai E, Ishiura S. β-Secretase inhibitor potency is decreased by aberrant β-cleavage location of the "Swedish Mutant" amyloid precursor protein. J Biol Chem. 2010;285:1634-42.
20. Thakker DR, Sankaranarayanan S, Weatherspoon MR, Harrison J, Pierdomenico M, Heisel JM, et al. Centrally delivered BACE1 inhibitor activates microglia, and reverses amyloid pathology and cognitive deficit in aged Tg2576 mice. J Neurosc. 2015;35:6931-6.
21. Abramowski D, Wiederhold KH, Furrer U, Jaton AL, Neuenschwander A, Runser MJ, et al. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther. 2008;327:411-24.
22. Jacobsen H, Ozmen L, Caruso A, Narquizian R, Hilpert H, Jacobsen B, et al. Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice. J Neurosci. 2014;34:11621-30.
23. Obulesu M, Jhansilakshimi M. Neuroinflammation in Alzheimer's disease: an understanding of physiology and pathology. Int J Neurosci. 2014;124:227-35.
24. Heneka MT, Rodrigues JJ, Verkhratsky A. Neuroglia in neurodegeneration. Brain Res Rev. 2010;63:189-211.
25. Latta CH, Brothers HM, Wilcock DM. Neuroinflammation in Alzheimer's disease; a source of heterogeneity and target for personalized therapy. Neuroscience, ahead of print. doi: 10.1016/j.neuroscience.2014.09.061.
26. Rochin L, Hurbain I, Serneels L, Fort C, Watt B, Leblanc P, et al. BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. Proc Natl Acad Sci USA. 2013;110:10658-63.
27. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012;2:a006346.
28. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:253-6.
29. Wohnsland F, Faller B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem. 2001;44:923-30.
30. Wan H, Rehngren M, Giordanetto F, Bergström F, Tunek A. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem. 2007;50:4606-15.
31. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, et al. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nature Neurosci. 2004;7:954-60.